It was just nine months ago that Idolsia announced a CEO change, appointing Srishti Gupta, MD, to its executive team starting July 2025. Now, without any explanation, Mr. Gupta has left the Swiss pharmaceutical company and stepped down from its board of directors.
On Monday morning, Idorcia said that Gupta and the board had “mutually agreed” that she would resign. Idosia is searching for a new CEO, while Chairman of the Board Jean-Paul Crozel, MD, is responsible for the day-to-day operations of the pharmaceutical company.
“It is a great honor to lead Idorsia and work with such a talented and dedicated team at such a critical time for the company,” Mr. Gupta said in a March 16 statement. “I am proud of what we have accomplished together in translating science into meaningful advances for patients. I wish Idorsia and all its stakeholders success in the future.”
Mr. Gupta was appointed CEO last summer and has been a member of Idorsia’s board since 2021.
Idorsia sells the insomnia drug Quviviq and the high blood pressure drug Tryvio. Last year, the company’s revenue reached (PDF) 221 million Swiss francs ($265 million), almost double the company’s total revenue from the previous year. Idorsia also dramatically reduced its operating losses during this period from CHF 232 million in 2024 to CHF 33 million in 2025.
Idolcia is investigating lucerastat, a potential oral treatment for patients with Fabry disease, and several first-in-class immunology candidates in its pipeline. The company is also touting drug-like synthetic glycan vaccine technology among its research and development department projects.
Idorsia cut nearly 200 jobs last year, according to last month’s full-year financial results. As of the end of 2019, the company had 487 full-time employees.
Idorcia’s stock price fell more than 10% on Monday morning following the announcement of a change in management.
